glp-1 kidney function Receptor Agonists and Protection GLP-1 agonists in the treatment

66 Notably, semaglutide and tirzepatide (GLP-1RA + GIPR agonist) have been approved for chronic weight management in non-diabetic obese patients due to its significant weight-reducing efficacy

Notably, weight loss had not plateaued at 52 weeks, suggesting potential for further reduction with continued treatment [44]

These medications work by mimicking the action of incretin hormones, which play a crucial role in regulating blood sugar levels and promoting weight loss

Mount Sinai Hospital has received funding for investigator-initiated preclinical studies from Novo Nordisk and Pfizer

By balancing enthusiasm for emerging data with clear communication, clinicians can support patients effectively without overpromising outcomes

The reconstitution technique is the same, but the concentration calculations produce very different numbers